Tscan Therapeutics Inc (TCRX)

Dec 23, 2025

TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Lynx1 Capital Management Lp Acquires 80,069 Shares - MarketBeat

Dec 23, 2025

Dec 23, 2025

TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Buys 75,500 Shares - MarketBeat

Dec 23, 2025

Dec 20, 2025

How TScan Therapeutics Inc. stock reacts to oil pricesTrade Risk Assessment & AI Forecasted Entry/Exit Points - Улправда

Dec 20, 2025

Dec 19, 2025

Why TScan Therapeutics Inc. stock is a must watch in 20252025 Top Decliners & Low Risk Entry Point Guides - Bölüm Sonu Canavarı

Dec 19, 2025

Dec 19, 2025

Is TScan Therapeutics Inc. stock safe for conservative investorsJuly 2025 Sector Moves & Stepwise Trade Signal Implementation - DonanımHaber

Dec 19, 2025

Dec 19, 2025

Will TScan Therapeutics Inc. stock see PE expansionEarnings Miss & Community Consensus Stock Picks - DonanımHaber

Dec 19, 2025

Dec 19, 2025

Is TScan Therapeutics Inc. stock dividend yield sustainable2025 Market Sentiment & Smart Investment Allocation Insights - Улправда

Dec 19, 2025

Dec 09, 2025

Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event By Investing.com - Investing.com South Africa

Dec 09, 2025

Dec 09, 2025

Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event - Investing.com Canada

Dec 09, 2025

Dec 09, 2025

TScan Therapeutics announces updated data from ALLOHA Phase 1 trial - MSN

Dec 09, 2025

Dec 08, 2025

TScan Therapeutics : ASH 2025 Virtual KOL Presentation - marketscreener.com

Dec 08, 2025

Dec 08, 2025

Wall Street analysts’ outlook for Tscan Therapeutics Inc (TCRX) - setenews.com

Dec 08, 2025

Dec 08, 2025

TCRX: TSC-101 shows durable efficacy and safety, with pivotal trial and market expansion set for next year - TradingView

Dec 08, 2025

Dec 06, 2025

Investor MeetingKey Opinion Leader - marketscreener.com

Dec 06, 2025

Dec 06, 2025

TScan Therapeutics Reports Promising Two-Year Relapse-Free Survival Data for TSC-101 in Phase 1 Trial for Hematologic Malignancies - Quiver Quantitative

Dec 06, 2025

Dec 06, 2025

TScan Therapeutics Announces Positive Updated Data from the - GlobeNewswire

Dec 06, 2025

Dec 06, 2025

How Low Can TScan Therapeutics Stock Really Go? - Trefis

Dec 06, 2025

Dec 06, 2025

TScan Therapeutics (TCRX) Price Target Increased by 10.53% to 7.14 - Nasdaq

Dec 06, 2025

Dec 06, 2025

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Analysts - MarketBeat

Dec 06, 2025

Dec 05, 2025

Is TScan Therapeutics Stock Built to Withstand a Pullback? - Trefis

Dec 05, 2025

Dec 04, 2025

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - KamloopsBCNow

Dec 04, 2025

Dec 04, 2025

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (2025-12-04) - Seeking Alpha

Dec 04, 2025

Dec 04, 2025

TScan to host KOL event discussing updated ALLOHA trial data By Investing.com - Investing.com Canada

Dec 04, 2025

Dec 04, 2025

TScan Therapeutics To Provide Update On Phase 1 Trial Of TSC-101 In Heme Malignancies Next Week - Nasdaq

Dec 04, 2025

Dec 03, 2025

TScan to host KOL event discussing updated ALLOHA trial data - Investing.com India

Dec 03, 2025

Dec 03, 2025

TScan Therapeutics to Host Virtual KOL Event on ALLOHA™ Phase 1 Trial Data and Market Opportunities - Quiver Quantitative

Dec 03, 2025

Dec 03, 2025

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities - The Manila Times

Dec 03, 2025

Nov 29, 2025

TScan Therapeutics, Inc. (TCRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Nov 29, 2025

Nov 28, 2025

Is TScan Therapeutics Inc a good long term investmentStock Liquidity Analysis & Free Tools to Find Winning Stocks - earlytimes.in

Nov 28, 2025

Nov 26, 2025

TScan Therapeutics Approves Key Employee Retention Program - TipRanks

Nov 26, 2025

Nov 26, 2025

TScan Therapeutics ties executive pay to pivotal TSC-101 trial - Stock Titan

Nov 26, 2025

Nov 24, 2025

American Society of Hematology Meeting - marketscreener.com

Nov 24, 2025

Nov 24, 2025

Cluey Ltd Launches $4.5 Million Entitlement Offer - The Globe and Mail

Nov 24, 2025

Nov 24, 2025

Tscan Therapeutics Inc (TCRX) is looking forward to a strong quarter - Setenews

Nov 24, 2025

Nov 21, 2025

Reversal indicators forming on TScan Therapeutics Inc. stockProfit Target & Consistent Profit Alerts - newser.com

Nov 21, 2025

Nov 21, 2025

Is TScan Therapeutics Inc. stock positioned well for digital economyTrade Ideas & Daily Oversold Bounce Ideas - newser.com

Nov 21, 2025

Nov 19, 2025

Applying chart zones and confluence areas to TScan Therapeutics Inc.2025 Pullback Review & Reliable Price Breakout Alerts - newser.com

Nov 19, 2025

Nov 19, 2025

Is TScan Therapeutics Inc. building a consolidation baseJuly 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com

Nov 19, 2025

Nov 17, 2025

How TScan Therapeutics Inc. stock performs in high volatility markets2025 Market Outlook & Expert Curated Trade Setups - newser.com

Nov 17, 2025

Nov 17, 2025

TScan Therapeutics (NASDAQ:TCRX) Cut to Equal Weight at Morgan Stanley - Defense World

Nov 17, 2025

Nov 17, 2025

Equities Analysts Issue Forecasts for TCRX FY2025 Earnings - Defense World

Nov 17, 2025

Nov 16, 2025

Best data tools to analyze TScan Therapeutics Inc. stockJuly 2025 Macro Moves & Daily Growth Stock Tips - newser.com

Nov 16, 2025

Nov 16, 2025

How TScan Therapeutics Inc. stock reacts to global recession fears2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com

Nov 16, 2025

Nov 16, 2025

HC Wainwright Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $7.00 - Defense World

Nov 16, 2025

Nov 15, 2025

Should you wait for a breakout in TScan Therapeutics Inc.Weekly Risk Summary & Scalable Portfolio Growth Methods - newser.com

Nov 15, 2025